Over the past few years, India’s pharmaceutical industry has been recognized for its ability to formulate and market generic medicines at competitive prices. In the past few years, this strength has been extended to the oncology space where Indian pharma companies are making significant headway in the bulk development of anticancer drugs. With global cancer cases on the rise and the cost of cancer treatment still prohibitive for many, India has an opportunity, and a responsibility, to provide life-saving therapies.
Globally, cancer kills more than 10 million people a year. In India, more than 1.5 million new cases are reported every year. Because of this, cancer is still one of the leading causes of death, resulting in a major public health challenge. In order to meet this demand, Indian pharma is rapidly increasing the supply of cancer drugs aimed at the generic and biosimilar segments, targeted for the domestic market and exports.
Indian firms have invested in high precision equipped cleanrooms, and automated facilities for consistent production.
Research and develop biosimilars and targeted therapies: India is recognized for generics; however, several companies have started developing complex biologics and targeted therapies for cancer, including monoclonal antibodies and kinase inhibitors.
Efficiency in production modelling: The costs of anticancer medicines can be produced at an extremely low cost because of the efficient scale of economies and well organized supply chains within the country.
Regulatory compliance: A considerable number of Indian pharmaceutical companies are recognized by the USFDA, EMA, and WHO-GMP, making them trusted suppliers for the international market.
Among the many anticancer drugs manufactured and distributed in bulk, Zytiga (Abiraterone Acetate) stands out as a vital treatment for metastatic prostate cancer. It works by inhibiting androgen production, which fuels the growth of prostate cancer cells. Zytiga is often prescribed alongside prednisone and is used in patients who have not responded to other therapies. Due to its high demand and cost, sourcing Zytiga in bulk—especially from reliable wholesalers—is essential for hospitals, pharmacies, and international buyers.
When it comes to sourcing Zytiga tablets, Lotus International has earned a reputation for excellence, reliability, and competitive pricing. Here’s why they stand out:
1.Authenticity and Quality Assurance
Lotus International deals directly with certified manufacturers and ensures that every batch of Zytiga meets stringent quality standards. Their supply chain is transparent, and they provide full documentation for regulatory compliance.
2.Competitive Pricing for Bulk Orders
By leveraging strong relationships with manufacturers and operating efficiently, Lotus International offers Zytiga tablets at highly competitive rates making them ideal for bulk buyers, including hospitals, distributors, and international importers.
3.Global Export Capabilities
Lotus International has a robust export infrastructure and is a leading Zytiga tablet wholesalers in India serves clients across the US, UK, Australia, and Africa. Their logistics team ensures timely delivery and handles all necessary customs and regulatory paperwork.
4.Customer-Centric Approach
What sets Lotus apart is their commitment to customer satisfaction. They offer flexible order volumes, responsive support, and tailored solutions for buyers with specific needs whether it’s a one-time shipment or a long-term supply contract.
5.Trusted by Healthcare Providers
Lotus International is frequently recommended by oncologists, pharmacists, and procurement managers for their consistency and professionalism. Their reputation in the oncology drug space is built on years of dependable service.
India’s pharmaceutical sector is rapidly evolving to meet the global challenge of cancer treatment. That’s why Anticancer drugs wholesalers in India, such as Lotus International, play a crucial role in ensuring timely, large-scale supply to international markets, supporting healthcare systems around the world.